To eliminate this confounding factor and generate data specifically reflecting the metabolic impact of IDO1 inhibition in vivo, we used an immunocompromised mouse model in which epacadostat had no impact on tumor growth under normal conditions (Liu et al., 2010). The gene discussed is IDO1; the disease is neoplasm.